Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T17:17:42.917Z.
Calculation as of: 2026-10-06T17:17:42.917Z.
Quote observation: 2026-10-06T17:13:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8dd4f1084baaf1fdd631c8004248db7003b46672aad8e0139030c30c223f55df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$17.14M
EV/EBITDA Ratio
N/A
TTM Avg
197.20x
3Y Avg
1380.98x
5Y Avg
1380.98x
Market Cap
$17.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.55M
EV/EBITDA Ratio
N/A
TTM Avg
95.14x
3Y Avg
74.72x
5Y Avg
74.72x
Market Cap
$17.79M
EV/EBITDA Ratio
N/A
TTM Avg
47.55x
3Y Avg
64.91x
5Y Avg
64.91x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.11M | N/A | N/A | N/A | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $17.14M | N/A | 197.20x | 1380.98x | 1380.98x |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | N/A | N/A | N/A | N/A |
| Lipocine Inc. (LPCN)vs › | $17.19M | N/A | 19.19x | 19.19x | 19.19x |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.74M | N/A | N/A | N/A | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | N/A | N/A | N/A | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.61M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.55M | N/A | 95.14x | 74.72x | 74.72x |
| Cosmos Health Inc. (COSM)vs › | $17.79M | N/A | 47.55x | 64.91x | 64.91x |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.93M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
